Locally Optimised Contouring With AI Technology for Radiotherapy

Last updated: March 6, 2025
Sponsor: Royal North Shore Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer Treatment

Treatment

AI assisted contouring

Clinical Study ID

NCT06546592
2024/PID01401
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring.

LOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years and older who are planned for primary breast malignancy

  • ECOG performance 0-2

  • Ability to understand and willingness to sign a written informed consent document

  • The target volume must be able to be objectively reviewed by current publishednational or international clinical guidelines

Exclusion

Exclusion Criteria:

  • Patients under 18 years of age

  • Patients unable to understand consent documents

Study Design

Total Participants: 444
Treatment Group(s): 1
Primary Treatment: AI assisted contouring
Phase:
Study Start date:
February 11, 2025
Estimated Completion Date:
April 30, 2030

Study Description

LOCATOR is a multicentre phase II non-inferiority randomised controlled trial looking at comparing AI assisted contours (with in-house LOCATOR software) against fully manual contouring in breast cancer patients. The primary endpoint is to show non inferiority in grade of AI assisted contouring when compared to fully manual contouring with a poor contour (score <= 2) as per the MD Anderson Contouring Grade Scale. Secondary endpoints include geometric assessments of contour accuracy, dosimetric differences based on contours, performance (geometric) when compared to commercially available tools as well as economic cost-benefit analysis if in-house AI contouring tools.

The study will randomise patients 3:1 to the intervention arm of LOCATOR assisted contours to manual contours. An initial AI contouring model for each tumor type will be trained on contours from 45 previous breast cases using a nnUNetv2 framework. The model will then be iteratively updated every 20-50 patients.

Connect with a study center

  • Western Cancer Centre Dubbo

    Dubbo, New South Wales 2830
    Australia

    Site Not Available

  • Central West Cancer Centre

    Orange, New South Wales 2800
    Australia

    Site Not Available

  • Department of Radiation Oncology, Royal North Shore Hospital

    St Leonards, New South Wales 2065
    Australia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.